Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

Journal of Clinical Pharmacology

Volumn 53, Issue 10, 2013, Pages 1028-1038

  Riggs, Matthew M ^a,d   Staab, Alexander ^b   Seman, Leo ^c   Macgregor, Thomas R ^c   Bergsma, Timothy T ^a   Gastonguay, Marc R ^a,d   Macha, Sreeraj ^c  

^a Metrum Research Group LLC   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d American College of Clinical Pharmacology   (United States)

Author keywords

Diabetes; Empagliflozin; Pharmacokinetics; Sglt2

Indexed keywords

EMPAGLIFLOZIN; METFORMIN; PLACEBO; SITAGLIPTIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE;

DIABETES; EMPAGLIFLOZIN; PHARMACOKINETICS; SGLT2;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84885170468     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.147     Document Type: Article

References (33)

1. International Diabetes Federation Diabetes Atlas Fourth Edition. Prevalence estimates of diabetes mellitus (DM), 2010. International Diabetes Federation, 2010. Available at: http://www.diabetesatlas.com/content/prevalence- estimates-diabetes-mellitus-dm-2010.
2. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288 (20):2579-2588. (Pubitemid 35386893)
3. Skljarevski V, Veves A. Impact of diabetes on vasculature: focus on nervous system. Curr Diabetes Rev. 2005;1(3):245-253.
4. Madonna R, De CR. Cellular and molecular mechanisms of vascular injury in diabetes-part I: pathways of vascular disease in diabetes. Vasc Pharmacol. 2011;54(3-6):68-74.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
6. Bergenstal RM, Bailey CJ, Kendall DM. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med. 2010;123(4):374.e9-374.e18.
7. Hernandez AV, Usmani A, Rajamanickam A, Moheet A. Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and metaregression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs. 2011;11(2):115-128.
8. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32(2):63-71.
9. Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551-559.
10. Heise T, Seman L, Macha S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with T2DM. Diabetes Ther. DOI: 10.1007/s13300- 013-0030-2 [Epub ahead of print].
11. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(7):613-621.
12. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650-657.
13. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14 (6):539-545.
14. Ferrannini E, Seman L, Seewaldt-Becker E, et al. A phase IIb, randomised, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721-728.
15. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34 (5):711-726. (Pubitemid 47477040)
16. R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2008.
17. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet. 1996;30(5):329-332. (Pubitemid 26177179)
18. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276(5309):122- 126. (Pubitemid 27161259)
19. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet. 1997;33(5):313-327. (Pubitemid 27480936)
20. Anderson BJ, Holford NH, Woollard GA, Chan PL. Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. Br J Clin Pharmacol. 1998;46(3):237-243. (Pubitemid 28404836)
21. Anderson BJ, Woollard GA, Holford NH. A model for size and age changes in the pharmacokinetics of paracetamol in neonates, infants and children. Br J Clin Pharmacol. 2000;50(2):125-134. (Pubitemid 30612030)
22. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian data analysis. New York: Chapman & Hall/CRC; 2004.
23. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28(2):171-192.
24. Post TM, Freijer JI, Ploeger BA, Danhof M. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35(2):185-202.
25. Gastonguay MR. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. Abstracts of the Annual Meeting of the Population Approach Group in Europe 2011; 20 Abstract 2229.
26. Riggs MM, Bergsma TT, Rogers JA, et al. Population pharmacokinetics and exposure-response of albinterferon alfa-2b. J Clin Pharmacol. 2012;52(4):475-486.
27. Hu C, Zhang J, Zhou H. Confirmatory analysis for phase III population pharmacokinetics. Pharm Stat. 2011;10(1):14-26.
28. Agoram B, Heatherington AC, Gastonguay MR. Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. AAPS J. 2006;8(3):E552- E563.
29. Gastonguay MR. A full model estimation approach for covariate effects: inference based on clinical importance and estimation precision. AAPS J. 2004;6(S1):W4354.
30. NONMEM users guide: part I-VII (1989-2006). Ellicott City, MD: Icon Development Solutions; 2006.
31. Jonsson EN, Karlsson MO. Automated covariate model building within NONMEM. Pharm Res. 1998;15(9):1463-1468. (Pubitemid 28427937)
32. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20(5):511-528. (Pubitemid 23034413)
33. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558-569.